EVANSTON, Ill., Feb. 27, 2014 /PRNewswire/ -- Naurex Inc. today announced that its president and chief executive officer, Norbert G. Riedel, Ph.D., will present at the Cowen and Company 34th Annual Health Care Conference on Tuesday, March 4, 2014 at 8:00 a.m. EST. Dr. Riedel will provide an overview of the company and discuss its two clinical-stage rapid-acting antidepressant drug candidates, GLYX-13 and NRX-1074.
The Cowen and Company 34th Annual Health Care Conference will be held March 3-5, 2014 at the Boston Marriott Copley Place in Boston, Massachusetts. For more information, visit www.cowen.com/conferences/upcoming-conferences/
About Naurex Inc.
Naurex is a clinical-stage biopharmaceutical company developing products to treat diseases of the central nervous system (CNS). The company's lead compound, GLYX-13, has shown promising rapid-acting antidepressant activity with excellent safety and no psychomimetic side effects in a Phase 2a clinical study. GLYX-13 is currently in a Phase 2b repeat-dose study as adjunctive therapy for major depressive disorder. Naurex's 2nd-generation antidepressant, NRX-1074, is in Phase 1 clinical studies. Naurex's proprietary platform for the discovery of novel compounds that act at the NMDA receptor to modulate neuronal plasticity has therapeutic potential in a number of CNS indications. For more information, visit www.naurex.com.
SOURCE Naurex, Inc.